Single-ascending doses of MAR002 showed a favourable tolerability and safety profile with no drug-related safety signals ...

The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers ...

Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh ...

Gyre Therapeutics announced positive results from its Phase 3 trial of Hydronidone, a treatment for liver fibrosis in patients with chronic hepatitis B (CHB), showing a significant regression in ...

BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

Company Shared Poster on Breakthrough Genetic Stratification Data from Positive Phase 2b OLIVE Trial Results for BH-200 ...

I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile. I-Mab has announced positive results from ...